Vericel announced the first U.S. implant of MACI® autologous cultured chondrocytes for the treatment of symptomatic knee cartilage defects.
This closely follows the 4Q16 FDA approval of MACI, indicated for the repair of symptomatic single or multiple full-thickness cartilage defects of the knee, with or without bone involvement, in adults. This represented the first FDA-approved cellularized scaffold to apply tissue engineering processes for growth of cells on scaffolds using healthy autologous cartilage.
Vericel announced the first U.S. implant of MACI® autologous cultured chondrocytes for the treatment of symptomatic knee cartilage defects.
This closely follows the 4Q16 FDA approval of MACI, indicated for the repair of symptomatic single or multiple full-thickness cartilage defects of the knee, with or without bone involvement, in adults....
Vericel announced the first U.S. implant of MACI® autologous cultured chondrocytes for the treatment of symptomatic knee cartilage defects.
This closely follows the 4Q16 FDA approval of MACI, indicated for the repair of symptomatic single or multiple full-thickness cartilage defects of the knee, with or without bone involvement, in adults. This represented the first FDA-approved cellularized scaffold to apply tissue engineering processes for growth of cells on scaffolds using healthy autologous cartilage.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
